Bhavesh Mohan Lal, MD, UAMS College of Medicine, Little Rock, Arkansas, reviews a study designed to investigate the effects of prior exposure to BCMA-targeting agents on outcomes with…
Praneeth Reddy Sudalagunta, PhD, applied research scientist, Moffitt Cancer Center, Tampa, Florida, discusses the differential effects of bridging therapy on the immune microenvironment as well as outcomes with…
Eunice Wang, MD, Chief of the Leukemia Service at Roswell Park Comprehensive Cancer Center, describes acute myeloid leukemia (AML) and details how emerging targeted treatments are transforming the…
In this interview, Omid Hamid, MD, discusses the current landscape of targeted therapies in melanoma. He shares his thoughts about immune response, triplet therapy, and soon-to-be-released data that…
Mark M. Awad, MD, PhD, assistant professor of Medicine at Harvard Medical School and clinical director of the Thoracic Oncology Treatment Center at Dana-Farber Cancer Institute, shares insights…
In this “Practice Pearls” roundtable organized by Pharmacy Times, expert panelists discuss acute myeloid leukemia (AML) diagnosis and the various factors affecting decision-making for specialists treating patients with…
Paula J. Bates, PhD, professor of medicine at the University of Louisville School of Medicine, and colleagues John O. Trent, PhD, and Donald M. Miller, MD, PhD, have…
A study published in Clinical Cancer Research, authored by James Brugarolas, MD, PhD, professor of internal medicine (hematology/oncology) and director of the Kidney Cancer Program at UT Southwestern, demonstrated…
Jason J. Luke, MD, FACP, an associate professor of medicine in the Division of Hematology/Oncology and director of the Cancer Immunotherapeutics Center within the Immunology and Immunotherapy Program at…
A study composed of patients from across the USA and Europe observed improved outcomes in those treated with both ilixadencel and sunitinib compared with sunitinib alone. here.
In this interview, Shirish M. Gadgeel, MD, MBBS, medical oncologist at Michigan Medicine, University of Michigan, provides insights into multikinase tyrosine kinase inhibitor (TKI) treatments and their varied…
A study completed by researchers in China, of patients with renal cell carcinoma (RCC), attempted to both validate previous conclusions and look at the influencing factors of perioperative renal…
